OB318 / Microbio, Oneness Biotech - LARVOL DELTA

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=21 | Terminated | Sponsor: Oneness Biotech Co., Ltd. | N=30 ➔ 21 | Recruiting ➔ Terminated; This decision is based on a strategic company decision to discontinue development of this program as part of our portfolio prioritization.

Enrollment change • Trial termination • Hepatocellular Cancer • Oncology • Solid Tumor

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Oneness Biotech Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Oneness Biotech Co., Ltd. | Trial primary completion date: May 2023 ➔ Dec 2023

Metastases • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Oneness Biotech Co., Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2019 ➔ Dec 2023; Trial primary completion date: Jun 2019 ➔ May 2023

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor